Plasminogen activator therapy for acute myocardial infarction has become standard medical
practice. Bleeding complications, however, limit the utility of the currently available agents …

Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium
and improving survival. This understanding has led to the application of genetic engineering …

The initial work on thrombolytic therapy for acute myocardial infarction (AMI) focused on
intracoronary administration of streptokinase. Continuing research has given rise to the …

Acute coronary ischemic syndromes and stroke are usually caused by thrombosis in arteries
where obstruction leads to ischemia of the heart or brain, respectively. Likewise, venous …

In this article we will compare plasminogen (Pig) activators in a unified manner, in order to
help clinical scientists and clinicians understand their use as thrombolytic agents in …

Cardiovascular disease is responsible for 17 million deaths per year but acute myocardial
infarction and stroke can be treated with thrombolytics (“clot busters”), which are …

Thrombotic occlusion of the coronary artery, which triggers acute myocardial infarction, is
one of the major causes of death in the USA. Currently, arterial occlusions are treated with …

Thrombolysis of obstructed coronary arteries by intravenous administration of plasminogen
activators has become an established treatment of acute myocardial infarction (for review …

Biochemical advances are providing new insights into coagulation and fibrinolysis.
Integrating this biochemical knowledge into plasminogen activator therapy improves …

Recombinant tissue-type plasminogen activator (rt-PA) and single chain urokinase-type
plasminogen activator (scu-PA) are thrombolytic agents, characterized by a high but not …